ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1959

The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis

Lihi Eder1, Ricardo Acayaba de Toledo2, Catherine Bakewell3, Philippe Carron4, Basant Elnady5, Amir Haddad6, Arthur Kavanaugh7, Fahmeen J. Afgani8, Arnon Katz9, Minna Kohler10, josefina marin11, Nam Nguyen12, Adrien NZEUSSEU TOUKAP13, Ari Polachek14, Ernesto Rodriguez15, Marcos Rosemffet16, Abha Singh17, Maria S. Stoenoiu18, Agnes Szentpetery19, Iliara Tinazzi20, Janeth Yinh21, Mu Yang22, Richard Cook22, Gurjit Kaeley23 and Sibel Aydin24, 1University of Toronto, Toronto, ON, Canada, 2Centro Integrado de Pesquisas (CIP) do Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil, 3Intermountain Healthcare Medical Group, Salt Lake City, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5Research Centre at Al Hada Armed Forces Hospital, Cairo, Egypt, 6Carmel Medical Center, Haifa, Israel, 7University of California, San Diego, School of Medicine, San Diego, CA, 8Women's College Hospital, Toronto, Canada, 9GRAPPA, Seattle, 10Massachusetts General Hospital, Harvard Medical School, Boston, MA, 11Hospital Universitario Rey Juan Carlos, Madrid, Spain, 12University of Toronto, Toronto, Canada, 13Cliniques Universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium, 14Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, 15Florida Medical Clinic, Tampa, 16Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 17Altman Clinical and Translational Research Institute, University of California San Diego, San Diego, CA, 18Cliniques Universitaires Saint-Luc, Brussels, Belgium, 19Uppsala University Hospital, Djursholm, Sweden, 20Ospedale Sacro Cuore-Don Calabria, Verona, Italy, 21Massachusetts General Hospital, Boston, MA, 22University of Waterloo, Waterloo, Canada, 23UF COM-J, Ponte Vedra Beach, FL, 24Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada

Meeting: ACR Convergence 2025

Keywords: Diagnostic criteria, Imaging, Psoriatic arthritis, Spondyloarthropathies, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1936–1971) Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Enthesitis is a key lesion in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a novel sonographic scoring system for enthesitis to aid PsA diagnosis.

Methods: We prospectively enrolled patients with early PsA, psoriasis alone, and people with non-inflammatory musculoskeletal symptoms as controls, across 17 centers. Participants underwent ultrasound assessment of 16 entheseal sites in the upper and lower extremities, performed by local sonographers. Images were centrally reviewed by 3 readers to derive a consensus score for inflammatory lesions (hypoechogenicity [0–1], thickening [0–1], power Doppler [PD, 0–3]) and structural lesions (calcification [0–3], enthesophyte [0–3], erosion [0–1]). Using a stepwise approach with logistic regression models stratified by age, we identified optimal combinations of lesions and their weighting, and entheseal sites that maximized the ability to distinguish PsA from controls. Data from the discovery cohort, supplemented by an existing validation dataset, were used to determine cut-off points that optimize sensitivity while maintaining specificity above 70%. We further evaluated the association between the DUET score and PsA disease activity measures.

Results: We analyzed 213 patients with PsA (mean duration 1.9±3.4 yrs), 100 with psoriasis and 106 controls. The mean age was 49.9±14.6 and 53.7% were females. Tenderness at ≥1 entheseal site was observed in 70% of PsA patients, 49% of controls and 33% of psoriasis (SPARCC score: PsA: 3.2, control: 2.5, psoriasis: 1.2). Initial evaluation of 4 inflammatory and 5 structural sub-scores across 16 entheseal sites yielded 48 candidate scores. Stratification by age improved discriminative performance. The best performing score (DUET score), comprising inflammatory (hypoechogenicity + thickening + 2×PD) and structural (enthesophyte + 3×erosion, Fig. 1) sub-scores at the Achilles, patellar tendon (patellar insertion), and triceps tendon, achieved an overall AUC of 0.65. Age-specific cut-offs (age cut off 55) yielded specificity of 73–74% and sensitivity of 47–49% (Fig. 2). In the validation cohort (101 PsA, 69 controls), specificity improved to 74–100% with comparable sensitivity (49–52%). Sensitivity increased up to 63% in patients with tender entheseal sites (Fig. 3). The mean DUET score was significantly higher in PsA compared with controls and psoriasis (9.07 vs. 5.48 and 6.38, respectively; p< 0.01 for both, Fig. 3). Scores were elevated among obese patients, those with tender entheses, and those about to escalate PsA therapy.

Conclusion: DUET is a newly developed sonographic tool that may assist in the diagnosis of PsA, particularly among individuals with tender entheseal sites. The findings suggests that large joint enthesitis is not a universal feature of early PsA.

Supporting image 1Figure 1: A summary of the DUET score. 1A. The DUET score formula is calculated based on a total of 6 entheseal sites: the Achilles and triceps insertions, and the patellar insertion to the patella. 1B–E. Depiction of selected elementary lesions and their corresponding DUET scores:

1B. Achilles tendon insertion showing thickening (1 point, vertical orange line) and enthesophyte (3 points, blue arrow); 1C. Achilles tendon insertion with erosion (1 point × 3, white arrow); 1D. Triceps tendon insertion with hypoechogenicity (1 point, yellow arrow) and enthesophyte (3 points, blue arrow); 1E. Patellar ligament insertion to the patella showing Doppler signal. The Doppler signal involves the area close to the bone (depicted by the orange marking), but the grading also considers Doppler intensity beyond this marking (3 points × 2).

Supporting image 2Figure 2: Performance of the DUET score.

2A. Correlation of the DUET score with age across disease groups; 2B. Discriminative ability of the DUET score (by AUC) across various age categories; 2C–2D. Sensitivity, specificity, AUC, and distribution of DUET scores in PsA and controls for the selected cut-off points among individuals aged ≤55 years and >55 years in the discovery (Fig. 2C) and validation (Fig. 2D) cohorts.

Supporting image 3Figure 3: Correlation between the DUET score and clinical measures. 3A. Mean DUET score (by inflammatory and structural sub-scores) is higher in PsA compared to controls and psoriasis; 3B. DUET sensitivity by the number of tender entheses; 3C. DUET sub-score by PsA sub-groups.


Disclosures: L. Eder: AbbVie, 1, 2, 5, 6, BMS, 1, 2, Eli Lilly, 1, 2, 5, 6, Fresenius Kabi, 1, 5, J&J, 1, 2, 5, Janssen, 1, 5, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, UCB, 1, 2, 5; R. Acayaba de Toledo: Abbvie, 5, 6, GSK, 6, Johnson & Johnson, 6, Novartis, 6, UCB, 6; C. Bakewell: AbbVie/Abbott, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Johnson & Johnson, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6, UCB, 2, 6; P. Carron: AbbVie/Abbott, 2, 6, Alfasigma, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Johnson & Johnson, 2, 6, Novartis, 2, 6, UCB, 2, 6; B. Elnady: None; A. Haddad: None; A. Kavanaugh: Amgen, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, 5, GRAPPA, 12, Co-President, Janssen, 2, 5, MoonLake Immunotherapeutics, 2, Pfizer, 2, 5, Takeda, 2, UCB, 2; F. Afgani: None; A. Katz: None; M. Kohler: Janssen, 5, 12, medical advisory board, Novartis, 12, medical advisory board, Setpoint Medical, 5, Springer Publications, 9; j. marin: None; N. Nguyen: None; A. NZEUSSEU TOUKAP: Amgen, 5, Eli Lilly, 1, 6, Janssen, 1, 5, 6, Novartis, 6; A. Polachek: None; E. Rodriguez: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Eli Lilly, 2, 5, 6, Johnson & Johnson, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6; M. Rosemffet: None; A. Singh: Sonoma Biotherapeutics, 5; M. Stoenoiu: AbbVie/Abbott, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6, UCB, 5, 6; A. Szentpetery: None; I. Tinazzi: None; J. Yinh: Janssen, 2, Springer, 9; M. Yang: None; R. Cook: None; G. Kaeley: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Janssen, 5, Novartis, 5; S. Aydin: AbbVie/Abbott, 5, 6, Eli Lilly, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, UCB, 5, 6.

To cite this abstract in AMA style:

Eder L, Acayaba de Toledo R, Bakewell C, Carron P, Elnady B, Haddad A, Kavanaugh A, Afgani F, Katz A, Kohler M, marin j, Nguyen N, NZEUSSEU TOUKAP A, Polachek A, Rodriguez E, Rosemffet M, Singh A, Stoenoiu M, Szentpetery A, Tinazzi I, Yinh J, Yang M, Cook R, Kaeley G, Aydin S. The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-development-and-validation-of-a-diagnostic-ultrasound-enthesitis-score-duet-for-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-development-and-validation-of-a-diagnostic-ultrasound-enthesitis-score-duet-for-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology